» Articles » PMID: 31906326

Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control

Overview
Publisher MDPI
Date 2020 Jan 8
PMID 31906326
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Type 2 diabetes mellitus (T2DM) is characterized by a prothrombotic state, predisposing to vascular complications. Some related markers, linking thrombophilia to hemostasis and inflammation, however, have been poorly explored in relation to patients' glycemia. We therefore investigated the association of laboratory hemostatic parameters, circulating adhesion molecules (ADMs), white blood cell (WBC) count, and neutrophil/lymphocyte ratio (NLR) with T2DM and glycemic control.

Research Design: In this study, 82 subjects, grouped into T2DM patients ( = 41) and healthy individuals ( = 41) were enrolled. To evaluate glycemic control, the T2DM cohort was expanded to 133 patients and sub-classified according to glycated hemoglobin (HbA1c) <7% and ≥ 7% ( = 58 and = 75, respectively). We assessed glycemia, HbA1c, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), platelet and leukocyte parameters, vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and selectins (E-, P-, L-).

Results: PT % activity, PAI-1, VCAM-1, WBC, and neutrophil counts were significantly higher in T2DM patients than in healthy subjects. Poor glycemic control (HbA1c ≥ 7%) was correlated with increased PT activity ( = 0.015), and higher levels of E-selectin ( = 0.009), P-selectin ( = 0.012), and NLR ( = 0.019).

Conclusions: Both T2DM and poor glycemic control affect some parameters of hemostasis, inflammation, and adhesion molecules. Further studies are needed to establish their clinical utility as adjuvant markers for cardio-vascular risk in T2DM patients.

Citing Articles

Comparison of clinical characteristics, microvascular complications and inflammatory markers in type 2 diabetic patients under insulin versus metformin treatment: A cross-sectional study at Karbala Diabetic Center, Iraq.

Mohammed H, Ben Othman R, Alghurabi H, Hussein R, Al-Obaidi Z, Abdesselem H Medicine (Baltimore). 2024; 103(44):e40330.

PMID: 39495998 PMC: 11537605. DOI: 10.1097/MD.0000000000040330.


Assessment of neutrophil/lymphocyte ratio and mean platelet volume values in patients with diabetes mellitus diagnosis: A case-control study.

Aygun K, Sakalli A, Kucukerdem H, Aygun O, Gokdemir O Medicine (Baltimore). 2024; 103(37):e39661.

PMID: 39287321 PMC: 11404952. DOI: 10.1097/MD.0000000000039661.


Luteolin Alleviates Diabetic Nephropathy Fibrosis Involving AMPK/NLRP3/TGF-β Pathway.

Huang R, Zeng J, Yu X, Shi Y, Song N, Zhang J Diabetes Metab Syndr Obes. 2024; 17:2855-2867.

PMID: 39100967 PMC: 11297584. DOI: 10.2147/DMSO.S450094.


Role of Decreased Expression of miR-155 and miR-146a in Peripheral Blood of Type 2 Diabetes Mellitus Patients with Diabetic Peripheral Neuropathy.

Ji H, Lu Y, Liu G, Zhao X, Xu M, Chen M Diabetes Metab Syndr Obes. 2024; 17:2747-2760.

PMID: 39072343 PMC: 11283243. DOI: 10.2147/DMSO.S467409.


Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.

Valencia I, Lumpuy-Castillo J, Magalhaes G, Sanchez-Ferrer C, Lorenzo O, Peiro C Cardiovasc Diabetol. 2024; 23(1):75.

PMID: 38378550 PMC: 10880237. DOI: 10.1186/s12933-023-02097-8.


References
1.
Zalewski G, Ciccarone E, Di Castelnuovo A, Zito F, Capani F, de Gaetano G . P-selectin gene genotypes or haplotypes and cardiovascular complications in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2006; 16(6):418-25. DOI: 10.1016/j.numecd.2005.07.002. View

2.
Dunn E, Ariens R, Grant P . The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48(6):1198-206. DOI: 10.1007/s00125-005-1742-2. View

3.
Stern M . Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995; 44(4):369-74. DOI: 10.2337/diab.44.4.369. View

4.
Grant P . Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007; 262(2):157-72. DOI: 10.1111/j.1365-2796.2007.01824.x. View

5.
Auwerx J, Bouillon R, Collen D, Geboers J . Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988; 8(1):68-72. DOI: 10.1161/01.atv.8.1.68. View